Lenacapavir: Revolutionary HIV Prevention Drug Named 2024 Breakthrough of the Year
A twice-yearly injection of lenacapavir provided 100% protection against HIV in the PURPOSE 1 clinical trial, marking a potential turning point in the fight against AIDS.
ScienceGNGV Editorial Team5 min read
Science Magazine named lenacapavir its 2024 Breakthrough of the Year. In the PURPOSE 1 clinical trial, the twice-yearly injection provided complete protection against HIV infection — none of the 2,134 women who received the drug in the trial contracted the virus.
The drug works through a novel mechanism, targeting multiple stages of the HIV life cycle simultaneously. Unlike daily pills, the long-acting injection only needs to be administered every six months, dramatically improving adherence.
"This could be transformative for HIV prevention," said Dr. Anthony Fauci. The breakthrough offers hope that the decades-long AIDS epidemic could finally be brought under control, especially in regions where daily medication regimens are challenging to maintain.
